Scarica l'app Stockscreener
1.26
10.53%
0.12
Dopo l'orario di chiusura:
1.24
-0.02
-1.59%
Precedente Chiudi:
$1.14
Aprire:
$1.19
Volume 24 ore:
739.54K
Relative Volume:
3.49
Capitalizzazione di mercato:
$58.74M
Reddito:
$42,000
Utile/perdita netta:
$-11.44M
Rapporto P/E:
-5.0562
EPS:
-0.2492
Flusso di cassa netto:
$-7.93M
1 W Prestazione:
+22.33%
1M Prestazione:
-8.03%
6M Prestazione:
-32.98%
1 anno Prestazione:
-25.00%
Intervallo 1D:
$1.17
$1.39
Intervallo di 1 settimana:
$0.91
$1.39
Portata 52W:
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Nome
Entera Bio Ltd
Settore
Industria
Telefono
972-2-532-7151
Indirizzo
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.26 | 58.74M | 42,000 | -11.44M | -7.93M | -0.2492 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-22 | Iniziato | Aegis Capital | Buy |
Entera Bio Ltd Borsa (ENTX) Ultime notizie
Entera Bio Ltd. Announces Private Placement and Securities Purchase Agreement for Phase 3 Osteoporosis Study Funding - minichart.com.sg
Entera Bio Announces $10 Million Private Placement Financing - TipRanks
Entera Bio Raises $10 Million in Private Placement With BVF Partners, Adds Registration Rights - TradingView
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug - Investing.com
Entera Bio raises $10M in private placement led by BVF Partners - au.investing.com
Fresh $10M gives Entera Bio runway for Phase 3 osteoporosis study - Stock Titan
ENTX Technical Analysis & Stock Price Forecast - Intellectia AI
Entera Bio Ltd. announced that it has received $10 million in funding from BVF Partners L.P. - MarketScreener
Net current asset value per share of Entera Bio Ltd. – LS:A2JQXP - TradingView
Stock market today: S&P 500, Dow futures gain as Trump calls Iran's new leaders 'very reasonable'—Palantir, Rezolve AI, Entera Bio in focus - MSN
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED) - Benzinga
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable' - Benzinga
Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In FocusState Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday - Sahm
Entera Bio Ltd. Advances First-in-Class Oral Peptide Therapies for Osteoporosis, Hypoparathyroidism, and Metabolic Diseases – 2026 Annual Report Highlights - minichart.com.sg
Entera Bio Reports $18.7 Million Net Loss for 2025 and $1.2 Million in Revenue - geneonline.com
Entera Bio Reports 2025 Results, Advances Oral Osteoporosis Pipeline - TipRanks
Entera Bio (NASDAQ:ENTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
ENTX: FDA-aligned EB613 Phase 3, pipeline advanced, net loss $11.4M, cash supports into Q3 2026 - TradingView
Entera 10-K: Revenue $0.042M, Loss Per Share $0.25 - TradingView
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Entera Bio (NASDAQ: ENTX) outlines oral osteoporosis and metabolic pipeline - Stock Titan
Entera Bio Ltd. Advances Oral Peptide Pipeline with Key FDA Submissions and Clinical Program Updates for Osteoporosis and Other Conditions - Quiver Quantitative
Entera Bio (NASDAQ: ENTX) 2025 loss widens as oral peptide pipeline advances - Stock Titan
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - Bitget
S P Trends: Should I invest in Entera Bio Ltd before earnings2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market - The Globe and Mail
If You Invested $1,000 in Entera Bio Ltd (ENTX) - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
What pushed Entera Bio (ENTX) to rally nearly 16% after hours - MSN
Entera Bio (ENTX) Expected to Announce Earnings on Friday - marketbeat.com
Analyst Upgrade: Is Entera Bio Ltd stock risky to hold now2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trend Review: Should I invest in Entera Bio Ltd before earnings2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Energy Moves: Can Entera Bio Ltd weather a recession2026 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline f - GuruFocus
Performance Recap: Is Entera Bio Ltd stock risky to hold now2026 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy - TipRanks
Entera Bio (NASDAQ:ENTX) Director Geno Germano Purchases 20,000 Shares - MarketBeat
Insider Buying: Geno Germano Acquires Additional Shares of Enter - GuruFocus
Entera Bio (ENTX) director buys 20,000 shares in open market - Stock Titan
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Director Sean Ellis buys 10,000 Entera Bio (ENTX) shares on market - Stock Titan
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX) - TipRanks
Entera Bio (NASDAQ:ENTX) Stock Price Down 3%Here's What Happened - MarketBeat
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Bitget
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio Submits Streamlined Phase 3 Plan for EB613 - TipRanks
Entera Bio submits streamlined Phase 3 protocol for EB613, seeks 12-month hip BMD primary endpoint - TradingView
Entera Bio (NASDAQ: ENTX) refines EB613 Phase 3 osteoporosis trial timeline - Stock Titan
Entera Bio submits streamlined phase 3 protocol to initiate registrational program for EB613 in postmenopausal women with osteoporosis - marketscreener.com
Entera Bio Ltd Azioni (ENTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):